Asembia's comprehensive HUB services program includes end-to-end product support and a web-based prescriber portal which will leverage the latest technology. The program also encompasses full reimbursement support, expert clinical patient outreach services provided through Asembia's URAC accredited call-center operations, prescription triage to a national network of pharmacies and detailed data reporting and analytics. The program has been developed to optimize patient care, prescription delivery and clinical outcomes.
"Utilizing Asembia's comprehensive HUB Services will ensure a white-glove patient experience, and support services that increase patient retention during the first 3 months of treatment and ensure we streamline the prescription process for physicians and patients who are prescribed Afrezza," added Michael Castagna, Chief Commercial Officer of MannKind.
Asembia, LLC (Asembia) is the industry's largest specialty pharmacy group contracting and service organization. Asembia provides comprehensive and cost-effective access to the nation's $100+ billion specialty pharmacy industry. Asembia offers pharmacy providers, manufacturers, health plans and wholesale distributors a total channel management solution through customized patient programs, prescription data management services, online platforms, and unique cost effective purchasing agreements for specialty pharmacy products. Asembia is also the founder and host of the nation's largest annual specialty pharmacy summit. For more information, visit Asembia at www.asembia.com
Sr. Director of Business Development
Logo - http://photos.prnewswire.com/prnh/20150623/225134LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/asembia-to-provide-hub-and-patient-support-services-for-mannkind-corporation-related-to-afrezza-insulin-human-inhalation-powder-300312427.html